Fig. 3.
Evaluation of FOLFOX–bevacizumab response by RECIST and CyCAR criteria together with CTCs VEGFR status. FR favorable response, NFR non-favorable response, w week
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.